Patent ID: 9353051
Filing Date: 2016-05-31
CPC Classification: A61K,A61P,C07C,C07D,Y02A

Claim Text:
1. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound selected from the group consisting of N-(4-Diethylsulfamoyl-phenyl)-2-(4-oxo-4H-quinazolin-3-yl)-acetamide; N-(5-Diethylsulfamoyl-2-methoxy-phenyl)-isobutyramide; N-(4-Diethylsulfamoyl-phenyl)-2-(4-oxo-4H-benzo[d][1,2,3]triazin-3-yl)-acetamide; N-(4-Diethylsulfamoyl-phenyl)-2-(1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-purin-7-yl)-acetamide; N-(4-Diethylsulfamoyl-phenyl)-2-(4-oxo-4H-thieno[2,3-d]pyrimidin-3-yl)-acetamide; N-(4-Diethylsulfamoyl-phenyl)-2-(1,4-dioxo-3,4-dihydro-1H-phthalazin-2-yl)-acetamide; N-(4-Diethylsulfamoyl-phenyl)-2-(1,3-dioxo-1H,3H-benzo[de]isoquinolin-2-yl)-acetamide; N-(4-Diethylsulfamoyl-phenyl)-2-(5,6-dimethyl-4-oxo-4H-thieno[2,3-d]pyrimidin-3-yl)-acetamide; N-(4-Diethylsulfamoyl-phenyl)-2-(6-ethyl-4-oxo-4H-thieno[2,3-d]pyrimidin-3-yl)-acetamide; N-(5-Diethylsulfamoyl-2-methyl-phenyl)-2-(7-nitro-4-oxo-4H-quinazolin-3-yl)-acetamide; N-(5-Diethylsulfamoyl-2-methoxy-phenyl)-2-(1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-purin-7-yl)-acetamide; N-(5-Diethylsulfamoyl-2-methoxy-phenyl)-butyramide; N-(5-Diethylsulfamoyl-2-methoxy-phenyl)-3-methyl-butyramide; N-(5-Diethylsulfamoyl-2-methoxy-phenyl)-2-phenyl-acetamide; 1-[2-(4-oxo-4H-quinazolin-3-yl)-acetyl]-2,3-dihydro-1H-indole-5-sulfonic acid diethylamide; N-(5-Diethylsulfamoyl-2-methoxy-phenyl)-2-(4-oxo-4H-benzo[d][1,2,3]triazin-3-yl)-acetamide; Pentanoic acid (5-diethylsulfamoyl-2-methoxy-phenyl)-amide; N-(4-Diethylsulfamoyl-phenyl)-2-(4-oxo-4H-thieno[3,2-d]pyrimidin-3-yl)-acetamide; 2-(7-Chloro-4-oxo-4H-quinazolin-3-yl)-N-(4-diethylsulfamoyl-phenyl)-acetamide; N-(4-Diethylsulfamoyl-phenyl)-2-(4-oxo-4H-benzo[4,5]furo[3,2-d]pyrimidin-3-yl)-acetamide; N-(5-Diethylsulfamoyl-2-isopropoxy-phenyl)-3-(4-oxo-4H-benzo[d][1,2,3]triazin-3-yl)-propionamide; N-(4-Diethylsulfamoyl-phenyl)-2-(8-methyl-4-oxo-4H-quinazolin-3-yl)-acetamide; N-(5-Diethylsulfamoyl-2-methoxy-phenyl)-3-(4-oxo-4H-benzo[d][1,2,3]triazin-3-yl)-propionamide; and N-(4-Diethylsulfamoyl-phenyl)-2-[ethyl-(4-oxo-3,4-dihydro-quinazolin-2-ylmethyl)-amino]-acetamide; wherein said pharmaceutical composition is suitable for administration in a human or animal and wherein said pharmaceutically acceptable carrier is selected form the group consisting of, dispersion aids, suspension aids, surface active agents, isotonic agents, thickening agents, emulsifying agents, preservatives, solid binders and lubricants.